- Home
- UGRO vs SNTI Comparison
UGRO vs SNTI Comparison
Compare UGRO & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- SNTI
- Stock Information
- Founded
- UGRO 2014
- SNTI 2016
- Country
- UGRO United States
- SNTI United States
- Employees
- UGRO N/A
- SNTI 48
- Industry
- UGRO Industrial Specialties
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- SNTI Health Care
- Exchange
- UGRO Nasdaq
- SNTI Nasdaq
- Market Cap
- UGRO 18.0M
- SNTI 18.2M
- IPO Year
- UGRO N/A
- SNTI N/A
- Fundamental
- Price
- UGRO $1.07
- SNTI $3.97
- Analyst Decision
- UGRO Strong Buy
- SNTI Strong Buy
- Analyst Count
- UGRO 2
- SNTI 1
- Target Price
- UGRO $5.63
- SNTI $12.00
- AVG Volume (30 Days)
- UGRO 55.3K
- SNTI 7.2M
- Earning Date
- UGRO 12-27-2024
- SNTI 11-14-2024
- Dividend Yield
- UGRO N/A
- SNTI N/A
- EPS Growth
- UGRO N/A
- SNTI N/A
- EPS
- UGRO N/A
- SNTI N/A
- Revenue
- UGRO $70,320,066.00
- SNTI N/A
- Revenue This Year
- UGRO $14.76
- SNTI $254.47
- Revenue Next Year
- UGRO $21.29
- SNTI $169.66
- P/E Ratio
- UGRO N/A
- SNTI N/A
- Revenue Growth
- UGRO 12.08
- SNTI N/A
- 52 Week Low
- UGRO $0.93
- SNTI $1.52
- 52 Week High
- UGRO $2.84
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- UGRO 33.37
- SNTI 47.37
- Support Level
- UGRO $1.17
- SNTI $3.60
- Resistance Level
- UGRO $1.19
- SNTI $5.96
- Average True Range (ATR)
- UGRO 0.11
- SNTI 1.02
- MACD
- UGRO -0.02
- SNTI -0.29
- Stochastic Oscillator
- UGRO 24.78
- SNTI 5.74
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.